Source: International Congress 2017 – What is new in COPD management and prognosis: findings from large studies?
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Martinez (New York, United States of America). Blood eosinophil (EOS) count, exacerbation rate and response to roflumilast in patients with severe COPD. 4962

Member's Comments

No comment yet.

Related content which might interest you: Blood eosinophil count and exacerbation risk in patients with COPD Source: Eur Respir J, 50 (1) 1700761; 10.1183/13993003.00761-2017 Year: 2017 Association between blood eosinophil count and risk of exacerbations in patients with COPD Source: International Congress 2017 – Biomarker-based asthma control Year: 2017 Minimal effect of inhaled corticosteroids (ICS) on blood eosinophil count in steroid-naïve COPD patients Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Blood eosinophils and exacerbation rate in COPD patients over three years Source: International Congress 2018 – Biomarkers and lung function in airway disease Year: 2018 Correlations between exacerbation rate and blood eosinophil levels in COPD patients Source: International Congress 2017 – Infection and exacerbation science Year: 2017 Blood eosinophil count as a predictor of treatment response in adult patients with chronic cough Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Relationship of blood eosinophil count to exacerbations in COPD Source: International Congress 2016 – Airway response to infection Year: 2016 The impact of high eosinophil count on hospitalizations in COPD patients Source: International Congress 2018 – Biomarkers of COPD Year: 2018 Systemic inflammation, blood eosinophils count and lung function in COPD patients Source: International Congress 2017 – Classifying COPD with multidimensional scores and biomarkers Year: 2017 Blood eosinophil count as a predictor of obstructive airway disease (OAD) in a high parasite burden setting Source: International Congress 2016 – Exploring mechanisms in health and disease Year: 2016 Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study Source: Eur Respir J, 51 (5) 1702523; 10.1183/13993003.02523-2017 Year: 2018 Effect of indacaterol/glycopyrronium (IND/GLY) vs salmeterol/fluticasone (SFC) on moderate or severe COPD exacerbations and lung function based on baseline blood eosinophil counts: Results from the FLAME study Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Late Breaking Abstract - Blood eosinophil count (EOS) can accurately predict responsiveness to inhaled corticosteroids (ICS) in COPD, but only if measured while patients are not receiving steroids. Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 Blood eosinophil counts in COPD patients compared to controls Source: Eur Respir J, 54 (4) 1900633; 10.1183/13993003.00633-2019 Year: 2019 Effect of COPD exacerbations on early lung function decline under maintenance therapy: blood eosinophil count asbiomarker Source: International Congress 2019 – Eosinophils and FeNO in airway diseases Year: 2019 Relationship of blood eosinophil count to exacerbations in asthma patients with a COPD diagnosis Source: International Congress 2015 – Epidemiological studies of asthma and allergy Year: 2015 Late Breaking Abstract - The blood eosinophils count as a predictor of the response for omalizumab (OMA) in patients suffering from severe allergic asthma Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019 FENO and blood eosinophil count as surrogate barkers of eosinophilic airway inflammation in patients with severe asthma Source: Annual Congress 2010 - Induced sputum in relation: a fresh look on phenotyping and monitoring Year: 2010 Effect of dupilumab on severe exacerbations and lung function in patients with baseline blood eosinophils =500 cells/µL Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020 Blood eosinophil count and risk of pneumonia hospitalisations in individuals with COPD Source: Eur Respir J, 51 (5) 1800120; 10.1183/13993003.00120-2018 Year: 2018